Baillie Gifford & CO Lyell Immunopharma, Inc. Call Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LYEL
# of Institutions
122Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$19.2 Million30.81% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$14.3 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$14.3 Million13.96% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$12.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$9.57 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $235M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...